Vimarsana
Biggest News Aggregation in the World

Page 20 - Sciences Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sciences Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sciences Group Today - Breaking & Trending Today

Curaleaf International Appoints Miles Worne As President - Vimarsana News

Curaleaf International Appoints Miles Worne As President

Antonio Costanzo to Remain with the Company to Focus on M&A and Regulatory Affairs New CPG-focused President to drive next phase of growth as the European cannabis market opens up Curaleaf

Liu Xiaobo and his Nobel peace prize - Pearls and Irritations - Vimarsana News

Liu Xiaobo and his Nobel peace prize - Pearls and Irritations

13 July 2022, five years since China’s human rights activist and Nobel Peace prize awarded Liu Xiaobo's death. The controversy revisited.

SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009 - Vimarsana News

SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009

07.07.2022 - The Company Continues to Evaluate Optimal Dosing for Patients with Acute Myeloid Leukemia and Lymphoma in Preparation for Phase 2NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), ... Seite 1

Down 58%, Wall Street Thinks This Growth Stock Could More Than Double - Vimarsana News

Down 58%, Wall Street Thinks This Growth Stock Could More Than Double

It's not a profitable stock yet, but prospects look good for the near future.

Source: fool.com
SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo - Vimarsana News

SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo

SELLAS Life Sciences Group, Inc.